InsiderSignal.AI

InsiderSignal.ai

ADPT - Adaptive Biotechnologies Corp

Insider Sale by Rubinstein Julie (Pres, COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Rubinstein Julie, serving as Pres, COO at Adaptive Biotechnologies Corp (ADPT), sold 179,703 shares at $13.21 per share, for a total transaction value of $2,374,058.00. Following this transaction, Rubinstein Julie now holds 507,934 shares of ADPT.

This sale represents a 26.00% decrease in Rubinstein Julie's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, March 11, 2026 and publicly disclosed via SEC Form 4 filing on Friday, March 13, 2026, 2 days after the trade was made.

Adaptive Biotechnologies Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Rubinstein Julie

Pres, COO

Julie Rubinstein is the President and Chief Operating Officer of Adaptive Biotechnologies, a commercial-stage biotech company focused on translating adaptive immune system genetics into clinical diagnostic and therapeutic products[[1]](https://www.adaptivebiotech.com/adaptive-leadership/julie-rubinstein/). Since joining the company in 2011, she has held progressively senior leadership roles overseeing Life Sciences Research, Clinical Diagnostics, Drug Discovery, Corporate Marketing, and Business Development, and was instrumental in the company's successful 2019 initial public offering[[1]](https://www.adaptivebiotech.com/adaptive-leadership/julie-rubinstein/). Prior to Adaptive, Rubinstein held worldwide commercial development positions at Pfizer Oncology specializing in cancer immunotherapy, and worked at Johnson & Johnson's Ethicon Endo-Surgery division where she helped commercialize a breast cancer diagnostic device across major European markets[[1]](https://www.adaptivebiotech.com/adaptive-leadership/julie-rubinstein/). She began her career as a financial analyst in Morgan Stanley's Global Health Care Group[[1]](https://www.adaptivebiotech.com/adaptive-leadership/julie-rubinstein/). Rubinstein holds a dual degree, summa cum laude and Phi Beta Kappa, from the University of Pennsylvania's Wharton School and Annenberg School of Communications with a minor in French, as well as an MBA from Harvard Business School[[1]](https://www.adaptivebiotech.com/adaptive-leadership/julie-rubinstein/). She serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York[[1]](https://www.adaptivebiotech.com/adaptive-leadership/julie-rubinstein/).

View full insider profile →

Trade Price

$13.21

Quantity

179,703

Total Value

$2,374,058.00

Shares Owned

507,934

Trade Date

Wednesday, March 11, 2026

4 days ago

SEC Filing Date

Friday, March 13, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Adaptive Biotechnologies Corp

Company Overview

No company information available
View news mentioning ADPT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4758851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime